Download PDF
Exp Clin Endocrinol Diabetes 2019; 127(05): 311-319
DOI: 10.1055/s-0043-124183
Article
© Georg Thieme Verlag KG Stuttgart · New York

Effects of Coenzyme Q10 Supplementation on Serum Values of Gamma-glutamyl transferase, Pseudocholinesterase, Bilirubin, Ferritin, and High-Sensitivity C-Reactive Protein in Women with Type 2 Diabetes

Mahsa Gholami
1   Student Research Committee, Arak University of Medical Sciences, Arak, Iran
,
Mohammad Reza Rezvanfar
2   Department of Internal Medicine, School of Medicine, Arak University of Medical Sciences, Arak, Iran
,
Mostafa Delavar
3   Department of Pharmacology, School of Medicine, Arak University of Medical Sciences, Arak, Iran
,
Mahdi Abdollahi
4   Expert of Control Laboratory Food and Beverage, Decorative, Hygienic Products of Arak’s Medical Sciences University, Arak University of Medical Sciences, Arak, Iran
,
Ali Khosrowbeygi
5   Department of Biochemistry and Genetics, School of Medicine, Arak University of Medical Sciences, Arak, Iran
› Author Affiliations
Further Information

Publication History

received 01 August 2017
revised 29 November 2017

accepted 05 December 2017

Publication Date:
24 January 2018 (online)

Also available at
    Permissions and Reprints

Abstract

Background Type 2 diabetes mellitus (T2DM) is a disease associated with increased oxidative stress which results from mitochondrial dysfunction. Coenzyme Q10 (CoQ10) is an essential antioxidant for energy production in mitochondria. The purpose of this randomized double-blind clinical trial study was to evaluate the effects of CoQ10 supplementation on serum values of gamma-glutamyl transferase (GGT), pseudocholinesterase (PchE), bilirubin, ferritin, and high-sensitivity c-reactive protein (hs-CRP) and metabolic syndrome biomarkers in women with T2DM.

Material & Methods Eighty women with T2DM enrolled in this study. Thirty six of them were randomized in the drug group (receiving 100 mg/day of CoQ10) and 44 women were randomized in placebo group. Intervention was continued for 12 weeks. In both groups 35 subjects finished the study and were included in the analysis. Serum levels of the variables were measured before and after supplementation.

Results Serum values of FBS (P=0.039), HOMA-IR (P=0.01), ferritin (P<0.001), total cholesterol (TC) (P=0.006), LDL-C (P=0.007) decreased and HDL-C (P=0.02) increased significantly in the drug group after intervention. Serum levels of triglyceride (P=0.09) decreased marginally in CoQ10 group.

Conclusions The results of the current study had shown that after supplementation with 100 mg/day of CoQ10 for 12 weeks, serum values of FBS, HOMA-IR, TC, LDL-C and ferritin were decreased and values of HDL-C were increased in women with T2DM.

Key words

type 2 diabetes - coenzyme Q10 - butyrylcholinesterase - gamma-glutamyl transferase - ferritin
 

  • References

  • 1 Guerrero-Romero F, Rodriguez-Moran M, González-Ortiz M. et al. Insulin action and secretion in healthy Hispanic-Mexican first-degree relatives of subjects with type 2 diabetes. J Endocrinol Invest 2001; 24: 580-586
    CrossrefPubMedGoogle Scholar
  • 2 Kunutsor SK, Abbasi A, Adler AI. Gamma-glutamyl transferase and risk of type II diabetes: An updated systematic review and dose-response meta-analysis. Ann Epidemiol 2014; 24: 809-816
    CrossrefPubMedGoogle Scholar
  • 3 Suksomboon N, Poolsup N, Juanak N. Effects of coenzyme Q10 supplementation on metabolic profile in diabetes: A systematic review and meta-analysis. J Clin Pharm Ther 2015; 40: 413-418
    CrossrefPubMedGoogle Scholar
  • 4 Shen Q, Pierce JD. Supplementation of coenzyme Q10 among patients with type 2 diabetes mellitus. Healthcare (Basel) 2015; 296-309
    PubMedGoogle Scholar
  • 5 Nadjarzadeh A, Sadeghi M, Amirjannati N. et al. Coenzyme Q10 improves seminal oxidative defense but does not affect on semen parameters in idiopathic oligoasthenoteratozoospermia: A randomized double-blind, placebo controlled trial. J Endocrinol Invest 2011; 34: e224-e228
    PubMedGoogle Scholar
  • 6 Farsi F, Mohammadshahi M, Alavinejad P. et al. Functions of Coenzyme Q10 supplementation on liver enzymes, markers of systemic inflammation, and adipokines in patients affected by nonalcoholic fatty liver disease: A double-blind, placebo-controlled, randomized clinical trial. J Am Coll Nutr 2016; 35: 346-353
    CrossrefPubMedGoogle Scholar
  • 7 Haghighi S, Amini M, Pournaghshband Z. et al. Relationship between gamma-glutamyl transferase and glucose intolerance in first degree relatives of type 2 diabetics patients. J Res Med Sci 2011; 16: 123
    PubMedGoogle Scholar
  • 8 Onur S, Niklowitz P, Jacobs G. et al. Ubiquinol reduces gamma glutamyltransferase as a marker of oxidative stress in humans. BMC Res Notes 2014; 7: 42
    CrossrefPubMedGoogle Scholar
  • 9 Santarpia L, Grandone I, Contaldo F. et al. Butyrylcholinesterase as a prognostic marker: A review of the literature. J Cachexia Sarcopenia Muscle 2013; 4: 31-39
    CrossrefPubMedGoogle Scholar
  • 10 Annapurna V, Senciall I, Davis A. et al Relationship between serum pseudocholinesterase and triglycerides in experimentally induced diabetes mellitus in rats. Diabetologia 1991; 34: 320-324
    CrossrefPubMedGoogle Scholar
  • 11 Rao AA, Sridhar GR, Das UN. Elevated butyrylcholinesterase and acetylcholinesterase may predict the development of type 2 diabetes mellitus and Alzheimer’s disease. Med Hypotheses 2007; 69: 1272-1276
    CrossrefPubMedGoogle Scholar
  • 12 Solecka J, Guśpiel A, Postek M. et al. New derivatives of 3, 4-dihydroisoquinoline-3-carboxylic acid with free-radical scavenging, D-amino acid oxidase, acetylcholinesterase and butyrylcholinesterase inhibitory activity. Molecules 2014; 19: 15866-15890
    CrossrefPubMedGoogle Scholar
  • 13 Hussan RM, Al-Khayat PDT. Relationship among Serum Level of Butyrylcholinesterase, Oxidative Stress and Lipid Profile in Premenopausal and Postmenopausal Iraqi Women. IJSER 2014; 5: 773-780
    PubMedGoogle Scholar
  • 14 Hamamoto S, Kaneto H, Kamei S. et al. Low bilirubin levels are an independent risk factor for diabetic retinopathy and nephropathy in Japanese patients with type 2 diabetes. Diabetes Metab 2015; 41: 429-431
    CrossrefPubMedGoogle Scholar
  • 15 Chung JO, Cho DH, Chung DJ. et al. The duration of diabetes is inversely associated with the physiological serum bilirubin levels in patients with type 2 diabetes. Intern Med 2015; 54: 141-146
    CrossrefPubMedGoogle Scholar
  • 16 Sridhar G, Nirmala G, Apparao A. et al. Serum butyrylcholinesterase in type 2 diabetes mellitus: A biochemical and bioinformatics approach. Lipids Health Dis 2005; 4: 18
    CrossrefPubMedGoogle Scholar
  • 17 Lin L-Y, Kuo H-K, Hwang J-J. et al. Serum bilirubin is inversely associated with insulin resistance and metabolic syndrome among children and adolescents. Atherosclerosis 2009; 203: 563-568
    CrossrefPubMedGoogle Scholar
  • 18 Liu J, Dong H, Zhang Y. et al. Bilirubin increases insulin sensitivity by regulating cholesterol metabolism, adipokines and PPARγ levels. Sci Rep 2015; 5: 09886
    CrossrefPubMedGoogle Scholar
  • 19 Esfahani SA, Esmaeilzadeh E, Bagheri F. et al. The effect of co-enzyme q10 on acute liver damage in rats, a biochemical and pathological study. Hepat Mon 2013; 13: e13685
    PubMedGoogle Scholar
  • 20 Momeni A, Behradmanesh MS, Kheiri S. et al. Serum ferritin has correlation with HbA1c in type 2 diabetic patients. Adv Biomed Res 2015; 4: 74
    CrossrefPubMedGoogle Scholar
  • 21 Bonfils L, Ellervik C, Friedrich N. et al. Fasting serum levels of ferritin are associated with impaired pancreatic beta cell function and decreased insulin sensitivity: A population-based study. Diabetologia 2015; 58: 523-533
    CrossrefPubMedGoogle Scholar
  • 22 Zhan Y, Tang Z, Yu J. Serum ferritin, diabetes, diabetes control, and insulin resistance. Acta Diabetol 2014; 51: 991-998
    CrossrefPubMedGoogle Scholar
  • 23 Kooncumchoo P, Sharma S, Porter J. et al. Coenzyme Q10 provides neuroprotection in iron-induced apoptosis in dopaminergic neurons. J Mol Neurosci 2006; 28: 125-141
    CrossrefPubMedGoogle Scholar
  • 24 Devaraj S, Singh U, Jialal I. Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol 2009; 20: 182
    CrossrefPubMedGoogle Scholar
  • 25 Iturry-Yamamoto G, Zago A, Moriguchi E. et al. Impact of metabolic syndrome and C-reactive protein on outcome after coronary stenting. J Endocrinol Invest 2009; 32: 383-386
    CrossrefPubMedGoogle Scholar
  • 26 Moazen M, Mazloom Z, Ahmadi A. et al. Effect of coenzyme Q10 on glycaemic control, oxidative stress and adiponectin in type 2 diabetes. J Pak Med Assoc 2015; 65: 404-408
    PubMedGoogle Scholar
  • 27 Lee B-J, Huang Y-C, Chen S-J. et al. Effects of coenzyme Q10 supplementation on inflammatory markers (high-sensitivity C-reactive protein, interleukin-6, and homocysteine) in patients with coronary artery disease. Nutrition 2012; 28: 767-772
    CrossrefPubMedGoogle Scholar
  • 28 Association AD . Diagnosis and classification of diabetes mellitus. Diabetes care 2014; 37: S81-S90
    CrossrefPubMedGoogle Scholar
  • 29 Hejazi ME, Modarresi-Ghazani F, Hamishehkar H. et al The Effect of Treatment of Vitamin D Deficiency on the Level of P-Selectin and hs‐CRP in Patients With Thromboembolism: A Pilot Randomized Clinical Trial. J Clin Pharmacol 2017; 57: 40-47
    CrossrefPubMedGoogle Scholar
  • 30 Heibashy M, El-Nahla A, Mazen G. et al. Assessment role of coenzyme Q10 on some physiological and biochemical parameters in resembling type II diabetic rats. Egypt J Basic Appl Physiol 2009; 8: 255-272
    PubMedGoogle Scholar
  • 31 Karpińska J, Mikołuć B, Motkowski R. et al. HPLC method for simultaneous determination of retinol, α-tocopherol and coenzyme Q 10 in human plasma. J Pharm Biomed Anal 2006; 42: 232-236
    CrossrefPubMedGoogle Scholar
  • 32 Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes care 2004; 27: 1487-1495
    CrossrefPubMedGoogle Scholar
  • 33 Nowotny K, Jung T, Höhn A. et al. Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules 2015; 5: 194-222
    CrossrefPubMedGoogle Scholar
  • 34 SHIGETA Y, IZUMI K. ABE H. Effect of coenzyme Q7 treatment on blood sugar and ketone bodies of diabetics. J Vitaminol 1966; 12: 293-298
    CrossrefPubMedGoogle Scholar
  • 35 Zahedi H, Eghtesadi S, Seifirad S. et al. Effects of CoQ10 Supplementation on Lipid Profiles and Glycemic Control in Patients with Type 2 Diabetes: a randomized, double blind, placebo-controlled trial. J Diabetes Metab Disord 2014; 13: 81
    CrossrefPubMedGoogle Scholar
  • 36 Singh R, Niaz M, Rastogi S. et al. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery. J Hum Hypertens 1999; 13: 203-208
    CrossrefPubMedGoogle Scholar
  • 37 Henriksen J, Andersen CB, Hother-Nielsen O. et al. Impact of ubiquinone (coenzyme Q10) treatment on glycaemic control, insulin requirement and well-being in patients with Type 1 diabetes mellitus. Diabet Med 1999; 16: 312-318
    CrossrefPubMedGoogle Scholar
  • 38 Eriksson J, Forsen T, Mortensen S. et al. The effect of coenzyme Q10 administration on metabolic control in patients with type 2 diabetes mellitus. Biofactors 1999; 9: 315-318
    CrossrefPubMedGoogle Scholar
  • 39 Lim SC, Lekshminarayanan R, Goh SK. et al. The effect of coenzyme Q 10 on microcirculatory endothelial function of subjects with type 2 diabetes mellitus. Atherosclerosis 2008; 196: 966-969
    CrossrefPubMedGoogle Scholar
  • 40 Hodgson J, Watts G, Playford D. et al. Coenzyme Q10 improves blood pressure and glycaemic control: A controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr 2002; 56: 1137
    CrossrefPubMedGoogle Scholar
  • 41 Mezawa M, Takemoto M, Onishi S. et al. The reduced form of coenzyme Q10 improves glycemic control in patients with type 2 diabetes: An open label pilot study. Biofactors 2012; 38: 416-421
    CrossrefPubMedGoogle Scholar
  • 42 Kolahdouz MR, Hosseinzadeh-Attar M, Eshraghian M. et al. The effect of coenzyme Q10 supplementation on metabolic status of type 2 diabetic patients. Minerva Gastroenterol Dietol 2013; 59: 231-236
    PubMedGoogle Scholar
  • 43 El-Hamid MA, El-Halim MS, Karima I. et al. Role of coenzyme Q10, metformin and rosiglitazone in treatment of experimental nonalcoholic steatohepatitis in rats. Tanta Med Sc J 2008; 3: 15e29
    PubMedGoogle Scholar
  • 44 Samimi M, Zarezade Mehrizi M, Foroozanfard F. et al. The effects of coenzyme Q10 supplementation on glucose metabolism and lipid profiles in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Clin Endocrinol 2017; 86: 560-566
    CrossrefPubMedGoogle Scholar
  • 45 Fakhrabadi MA, Ghotrom AZ, Mozaffari-Khosravi H. et al. Effect of Coenzyme Q10 on oxidative stress, glycemic control and inflammation in diabetic neuropathy: A double blind randomized clinical Trial. Int J Vitam Nutr Res 2014; 84: 252-260
    CrossrefPubMedGoogle Scholar
  • 46 Amin MM, Asaad GF, Salam RMA. et al. Novel CoQ10 antidiabetic mechanisms underlie its positive effect: Modulation of insulin and adiponectine receptors, Tyrosine kinase, PI3K, glucose transporters, sRAGE and visfatin in insulin resistant/diabetic rats. PloS one 2014; 9: e89169
    CrossrefPubMedGoogle Scholar
  • 47 Sena CM, Nunes E, Gomes A. et al. Supplementation of coenzyme Q 10 and α-tocopherol lowers glycated hemoglobin level and lipid peroxidation in pancreas of diabetic rats. Nutr Res 2008; 28: 113-121
    CrossrefPubMedGoogle Scholar
  • 48 Watts G, Playford D, Croft K. et al. Coenzyme Q10 improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus. Diabetologia 2002; 45: 420-426
    CrossrefPubMedGoogle Scholar
  • 49 Mohseni M, Vafa MR, Hajimiresmail SJ. et al. Effects of coenzyme q10 supplementation on serum lipoproteins, plasma fibrinogen, and blood pressure in patients with hyperlipidemia and myocardial infarction. Iran Red Crescent Med J 2014; 16: e16433
    PubMedGoogle Scholar
  • 50 Mehrdadi P, Mohammadi RK, Alipoor E. et al. The effect of coenzyme q10 supplementation on circulating levels of novel adipokine adipolin/CTRP12 in overweight and obese patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2017; 125: 156-162
    Article in Thieme ConnectPubMedGoogle Scholar
  • 51 Alam MA, Rahman MM. Mitochondrial dysfunction in obesity: Potential benefit and mechanism of Co-enzyme Q10 supplementation in metabolic syndrome. J Diabetes Metab Disord 2014; 13: 60
    CrossrefPubMedGoogle Scholar
  • 52 Forlani G, Di Bonito P, Mannucci E. et al Prevalence of elevated liver enzymes in Type 2 diabetes mellitus and its association with the metabolic syndrome. J Endocrinol Invest 2008; 31: 146-152
    CrossrefPubMedGoogle Scholar
  • 53 Kalpravidh RW, Wichit A, Siritanaratkul N. et al. Effect of coenzyme Q10 as an antioxidant in β-thalassemia/Hb E patients. Biofactors 2005; 25: 225-234
    CrossrefPubMedGoogle Scholar
  • 54 Eisenstein RS. Iron regulatory proteins and the molecular control of mammalian iron metabolism. Annu Rev Nutr 2000; 20: 627-662
    CrossrefPubMedGoogle Scholar
  • 55 Liu B-w, Xuan X-m, Liu J-r. et al The relationship between serum ferritin and insulin resistance in different glucose metabolism in nonobese Han adults. Int J Endocrinol 2015; 2015: 642194 doi:10.1155/2015/642194
    PubMedGoogle Scholar
  • 56 Kalender Y, Uzunhisarcikli M, Ogutcu A. et al. Effects of diazinon on pseudocholinesterase activity and haematological indices in rats: the protective role of vitamin E. Environ Toxicol Pharmacol 2006; 22: 46-51
    CrossrefPubMedGoogle Scholar
  • 57 ALTUNTAŞ İ, DELİBAŞ N. The effects of fenthion on lipid peroxidation and some liver enzymes: the possible protective role of vitamins E and C. Turk J Med Sci 2002; 32: 293-297
    PubMedGoogle Scholar